Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., … Weissman, I. L. (2004). Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. NEW ENGLAND JOURNAL OF MEDICINE, 351(7), 657–67.

Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
Gotlib, J. (2005). Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Current Hematology Reports, 4(1), 77–84.

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
Gotlib, J., Berube, C., Growney, J. D., Chen, C. C., George, T. I., Williams, C., … Coutre, S. E. (2005). Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. BLOOD, 106(8), 2865–70.

Molecular classification and pathogenesis of eosinophilic disorders: 2005 update
Gotlib, J. (2005). Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. ACTA HAEMATOLOGICA, 114(1), 7–25.

Eosinophilic disorders: Molecular pathogenesis, new classification, and modern therapy
Gotlib, J., Cross, N. C. R., & Gilliland, D. G. (2006). Eosinophilic disorders: Molecular pathogenesis, new classification, and modern therapy. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 19(3), 535–569.

Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis
Lay, M., Mariappan, R., Gotlib, J., Dietz, L., Sebastian, S., Schrijver, I., & Zehnder, J. L. (2006). Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. JOURNAL OF MOLECULAR DIAGNOSTICS, 8(3), 330–34.

A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance
Fukumoto, J. S., & Gotlib, J. (2006). A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance. AMERICAN JOURNAL OF HEMATOLOGY, 81(11), 870–74.

KIT mutations in mastocytosis and their potential as therapeutic targets
Gotlib, J. (2006). KIT mutations in mastocytosis and their potential as therapeutic targets. IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 26(3), 575-?

Use of urine flow cytometry to verify relapse of Burkitt's lymphoma in the genitourinary system
Dormady, S. P., Mariappan, M. R., Kao, D., & Gotlib, J. (2006). Use of urine flow cytometry to verify relapse of Burkitt's lymphoma in the genitourinary system. JOURNAL OF CLINICAL ONCOLOGY, 24(27), 4515–16.

Gene expression and pathway analysis of immune thrombocytopenic purpura
Sood, R., Wong, W., Gotlib, J., Jeng, M., & Zehnder, J. L. (2008). Gene expression and pathway analysis of immune thrombocytopenic purpura. BRITISH JOURNAL OF HAEMATOLOGY, 140(1), 99–103.

Chronic eosinophilic leukemia/hypereosinophilic syndrome.
Gotlib, J. (2008). Chronic eosinophilic leukemia/hypereosinophilic syndrome. Cancer Treatment and Research, 142, 69–106.

Selective inhibition of JAK2-Driven erythroid differentiation of polycythemia vera progenitors
Geron, I., Abrahamsson, A. E., Barroga, C. F., Kavalerchik, E., Gotlib, J., Hood, J. D., … Jamieson, C. H. M. (2008). Selective inhibition of JAK2-Driven erythroid differentiation of polycythemia vera progenitors. CANCER CELL, 13(4), 321–330.

Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias
Gotlib, J., & Cools, J. (2008). Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. LEUKEMIA, 22(11), 1999–2010.

A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes
Gotlib, J., Lavori, P., Quesada, S., Stein, R. S., Shahnia, S., & Greenberg, P. L. (2009). A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. AMERICAN JOURNAL OF HEMATOLOGY, 84(1), 15–20.

Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system
Weinberg, O. K., Seetharam, M., Ren, L., Seo, K., Ma, L., Merker, J. D., … Arber, D. A. (2009). Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. BLOOD, 113(9), 1906–8.

Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation
Abrahamsson, A. E., Geron, I., Gotlib, J., Dao, K.-H. T., Barroga, C. F., Newton, I. G., … Jamieson, C. H. M. (2009). Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(10), 3925–29.

Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens
Fan, A. C., Deb-Basu, D., Orban, M. W., Gotlib, J. R., Natkunam, Y., O'Neill, R., … Felsher, D. W. (2009). Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. NATURE MEDICINE, 15(5), 566–71.

RNAi screen for rapid therapeutic target identification in leukemia patients
Tyner, J. W., Deininger, M. W., Loriaux, M. M., Chang, B. H., Gotlib, J. R., Willis, S. G., … Druker, B. J. (2009). RNAi screen for rapid therapeutic target identification in leukemia patients. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(21), 8695–8700.

Monoclonal antibodies against IREM-1: potential for targeted therapy of AML
Korver, W., Zhao, X., Singh, S., Pardoux, C., Zhao, J., Guzman, M. L., … Abo, A. (2009). Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. LEUKEMIA, 23(9), 1587–97.

Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission
Medeiros, B. C., Gotlib, J., & Zehnder, J. (2009). Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission. LEUKEMIA & LYMPHOMA, 50(5), 851–53.

Novel biospecific agents for the treatment of myelodysplastic syndromes.
Gotlib, J., & Greenberg, P. L. (2003). Novel biospecific agents for the treatment of myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network , 1(4), 473–80.

When yellow jackets attack: recurrent and severe anaphylactic reactions to insect bites and stings
Pollyea, D. A., George, T. I., Corless, C., & Gotlib, J. (2009). When yellow jackets attack: recurrent and severe anaphylactic reactions to insect bites and stings. AMERICAN JOURNAL OF HEMATOLOGY, 84(12), 843–46.

On being metachromatic: mystique and misunderstanding in mastocytosis
Gotlib, J. (2009). On being metachromatic: mystique and misunderstanding in mastocytosis. AMERICAN JOURNAL OF HEMATOLOGY, 84(12), 779–81.

Design and Evaluation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-Type JAK2 Transcript Levels in the Clinical Laboratory
Merker, J. D., Jones, C. D., Oh, S. T., Schrijver, I., Gotlib, J., & Zehnder, J. L. (2010). Design and Evaluation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-Type JAK2 Transcript Levels in the Clinical Laboratory. JOURNAL OF MOLECULAR DIAGNOSTICS, 12(1), 58–64.

Eosinophilic myeloid disorders: new classification and novel therapeutic strategies
Gotlib, J. (2010). Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. CURRENT OPINION IN HEMATOLOGY, 17(2), 117–24.

Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms
Hidalgo-Curtis, C., Apperley, J. F., Stark, A., Jeng, M., Gotlib, J., Chase, A., … Grand, F. H. (2010). Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms. BRITISH JOURNAL OF HAEMATOLOGY, 148(2), 268–73.

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
Oh, S. T., Simonds, E. F., Jones, C., Hale, M. B., Goltsev, Y., Gibbs, K. D., … Gotlib, J. (2010). Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. BLOOD, 116(6), 988–92.

Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
Oh, S. T., & Gotlib, J. (2008). Antiangiogenic therapy in myelodysplastic syndromes: is there a role? Current Hematologic Malignancy Reports, 3(1), 10–18.

Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge
Arredondo, A. R., Gotlib, J., Shier, L., Medeiros, B., Wong, K., Cherry, A., … George, T. I. (2010). Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge. AMERICAN JOURNAL OF HEMATOLOGY, 85(8), 600–606.

Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., … Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877–81.

JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms
Oh, S. T., & Gotlib, J. (2010). JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. EXPERT REVIEW OF HEMATOLOGY, 3(3), 323–37.

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., … Tefferi, A. (2011). Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 789–796.

World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Gotlib, J. (2011). World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. American Journal of Hematology, 86(8), 677–88.

Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors
Pollyea, D. A., Raval, A., Kusler, B., Gotlib, J. R., Alizadeh, A. A., & Mitchell, B. S. (2011). Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. HEMATOLOGICAL ONCOLOGY, 29(3), 157–60.

Treatment advances have not improved the early death rate in acute promyelocytic leukemia
McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., Alizadeh, A. A., & Medeiros, B. C. (2012). Treatment advances have not improved the early death rate in acute promyelocytic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 133–36.

Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., … Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30–37.

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., … Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893–901.

Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia
Medeiros, B. C., Kohrt, H. E., Gotlib, J., Coutre, S. E., Zhang, B., Arber, D. A., & Zehnder, J. L. (2012). Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(1), 45–50.

A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia.
Zhang, B., Ng, D., Jones, C., Oh, S. T., Nolan, G. P., Salehi, S., … Gotlib, J. (2011). A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia. Blood, 118(26), 6988–90.

Mast Cells and Eosinophils in Mastocytosis, Chronic Eosinophilic Leukemia, and Non-clonal Disorders
Gotlib, J., & Akin, C. (2012). Mast Cells and Eosinophils in Mastocytosis, Chronic Eosinophilic Leukemia, and Non-clonal Disorders. SEMINARS IN HEMATOLOGY, 49(2), 128–37.

DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups
Ohgami, R. S., Ma, L., Ren, L., Weinberg, O. K., Seetharam, M., Gotlib, J. R., & Arber, D. A. (2012). DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups. BRITISH JOURNAL OF HAEMATOLOGY, 159(2), 182–90.

World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
Gotlib, J. (2012). World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology, 87(9), 903–14.

Accessory splenules in autoimmune hemolytic anemia.
Logan, A., Berube, C., & Gotlib, J. (2013). Accessory splenules in autoimmune hemolytic anemia. American Journal of Hematology, 88(2), 156-?

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., … Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 98(4), 591–96.

ICON: Eosinophil Disorders.
Valent, P., Klion, A. D., Rosenwasser, L. J., Arock, M., Bochner, B. S., Butterfield, J. H., … Gleich, G. J. (2012). ICON: Eosinophil Disorders. The World Allergy Organization Journal, 5(12), 174–81.

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
Gotlib, J., Pardanani, A., Akin, C., Reiter, A., George, T., Hermine, O., … Valent, P. (2013). International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. BLOOD, 121(13), 2393–2401.

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
Mesa, R. A., Gotlib, J., Gupta, V., Catalano, J. V., Deininger, M. W., Shields, A. L., … Verstovsek, S. (2013). Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. JOURNAL OF CLINICAL ONCOLOGY, 31(10), 1285–1292.

Next-generation sequencing in hematologic malignancies: what will be the dividends?
Merker, J. D., Valouev, A., & Gotlib, J. (2012). Next-generation sequencing in hematologic malignancies: what will be the dividends? Therapeutic Advances in Hematology, 3(6), 333–39.

SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis
Pardanani, A., Gotlib, J., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R., … Tefferi, A. (2011). SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis. BLOOD, 118(21), 1640–1640.

Missplicing of glycogen synthase kinase 3 beta: A potential mechanism of blast crisis chronic myeloid leukemia stem cell generation
Abrahamsson, A., Geron, I., Gotlib, J., Dao, K.-H., Giles, F., Newton, I., … Jamieson, C. H. M. (2007). Missplicing of glycogen synthase kinase 3 beta: A potential mechanism of blast crisis chronic myeloid leukemia stem cell generation. BLOOD, 110(11), 238A–239A.

NPM1 Haploinsufficiency Results in Increased Numbers of Hematopoietic Stem Cells and Progenitor Cells
Raval, A., Park, C. Y., Pang, W. W., Kusler, B., Sridhar, K. J., Gotlib, J. R., … Mitchell, B. S. (2009). NPM1 Haploinsufficiency Results in Increased Numbers of Hematopoietic Stem Cells and Progenitor Cells. BLOOD, 114(22), 307–.

Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study
McGuire, A., Shier, L. R., Gotlib, J., Medeiros, B., Wong, K., Corless, C., … George, T. I. (2009). Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study. Presented at the 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, BOSTON,MA: NATURE PUBLISHING GROUP.

Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., … Kantarjian, H. M. (2011). Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I. BLOOD, 118(21), 128–129.

Whole Genome Sequence Analysis of Primary Myelofibrosis.
Merker, J. D., Roskin, K., Ng, D., Pan, C., Fisk, D. G., Jones, C. D., … Gotlib, J. (2012). Whole Genome Sequence Analysis of Primary Myelofibrosis. BLOOD. ATLANTA,GA,GA,GA,GA,GA,GA,GA,GA: AMER SOC HEMATOLOGY.

Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21).

A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma
Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., Medeiros, B. C., & Liedtke, M. (2012). A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma. BLOOD, 120(21).

Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification
Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., Liedtke, M., … Zehnder, J. L. (2010). Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification. BLOOD, 116(21), 1357–58.

A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2010). A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 116(21), 1347–47.

Gene expression profile of idiopathic thrombocytopenic purpura (ITP) reveals elevated expression of interferon regulated genes.
Sood, R., Wong, W., Gotlib, J., Jeng, M., & Zehnder, J. L. (2006). Gene expression profile of idiopathic thrombocytopenic purpura (ITP) reveals elevated expression of interferon regulated genes. BLOOD, 108(11), 211A–211A.

Identification of a Novel Splice Donor Mutation In the Thrombopoietin Gene In a Philippine Family with Hereditary Thrombocythemia
Gotlib, J., Zhang, B., Jones, C. D., Riess, J., Wong, W. B., Simonds, E. F., … Zehnder, J. L. (2010). Identification of a Novel Splice Donor Mutation In the Thrombopoietin Gene In a Philippine Family with Hereditary Thrombocythemia. BLOOD. ORLANDO,FL,FL,FL,FL,FL,FL,FL,FL: AMER SOC HEMATOLOGY.

A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia
Ng, D., Jones, C., Oh, S. T., Nolan, G. P., Salehi, S., Wong, W., … Gotlib, J. (2011). A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia. BLOOD, 118(26), 6988-?

Loss of CD25 Expression in Advanced Systemic Mastocytosis Patients Treated with Midostaurin (PKC412)
Kunder, C. A., DeAngelo, D. J., Gotlib, J. R., Gitana, G., Atwater, S. K., & George, T. I. (2012). Loss of CD25 Expression in Advanced Systemic Mastocytosis Patients Treated with Midostaurin (PKC412). Presented at the 101st Annual Meeting of United-States-and-Canadian-Academy-of-Pathology (USCAP), VANCOUVER,CANADA,CANADA: NATURE PUBLISHING GROUP.

Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System
Weinberg, O. K., Seetharam, M., Ren, L., Ma, L., Seo, K., Merker, J., … Arber, D. A. (2009). Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System. Presented at the 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, BOSTON,MA,MA,MA,MA: NATURE PUBLISHING GROUP.

Significance of NPM1 and FLT3 mutations in acute myeloid leukemia with multilineage dysplasia: Does NPM1 identify a lower risk group?
Weinberg, O., Merker, J., Beck, A., Seetharam, M., Gotlib, J., Zehnder, J., & Arber, D. A. (2008). Significance of NPM1 and FLT3 mutations in acute myeloid leukemia with multilineage dysplasia: Does NPM1 identify a lower risk group? Presented at the 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, DENVER,CO,CO,CO,CO: NATURE PUBLISHING GROUP.

Clinical Characterization of Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System
Weinberg, O. K., Seetharam, M., Ren, L., Ma, L., Seo, K., Merker, J. D., … Arber, D. A. (2008). Clinical Characterization of Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System. BLOOD, 112(11), 341–42.

Design and Validation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-type JAK2 Transcript Levels
Merker, J. D., Jones, C. D., Oh, S. T., Khan, S., Schrijver, I., Gotlib, J., & Zehnder, J. L. (2008). Design and Validation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-type JAK2 Transcript Levels. JOURNAL OF MOLECULAR DIAGNOSTICS, 10(6), 581–81.

Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.
Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., Kohrt, H. E., & Medeiros, B. C. (2009). Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. BLOOD, 114(22), 420–21.

Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders
Oh, S. T., Zahn, J. M., Jones, C. D., Zhang, B., Loh, M. L., Kantarjian, H., … Gotlib, J. (2010). Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders. BLOOD. ORLANDO,FL,FL,FL,FL,FL,FL,FL,FL: AMER SOC HEMATOLOGY.

Correlation of Symptom Assessment with Genotyping Analysis of Saliva Samples in a Large Cohort of Myeloproliferative Neoplasm Patients
Nguyen, H. (M., Hinds, D. A., Barnholt, K. E., Kiefer, A. K., Do, C. B., Eriksson, N., … Mesa, R. A. (2012). Correlation of Symptom Assessment with Genotyping Analysis of Saliva Samples in a Large Cohort of Myeloproliferative Neoplasm Patients. BLOOD. ATLANTA,GA,GA,GA,GA,GA: AMER SOC HEMATOLOGY.

FDA-Approved Ruxolitinib in Patients with Myelofibrosis: the Stanford Experience
Nguyen, H. (M., Anh Pham, A., Perkins, C., Linder, A., Fechter, L., & Gotlib, J. (2012). FDA-Approved Ruxolitinib in Patients with Myelofibrosis: the Stanford Experience. BLOOD, 120(21).

Estimation of JAK2 V617F Prevalence by Detection of the Mutation in Saliva Samples From Online MPN and General Population Cohorts
Barnholt, K. E., Hinds, D. A., Kiefer, A. K., Do, C. B., Eriksson, N., Mountain, J. L., … Zehnder, J. L. (2012). Estimation of JAK2 V617F Prevalence by Detection of the Mutation in Saliva Samples From Online MPN and General Population Cohorts. BLOOD. ATLANTA,GA,GA,GA,GA,GA: AMER SOC HEMATOLOGY.

BCL2 Splice Isoform Switching Promotes Leukemia Stem Cell Survival and Sensitivity to a Novel Pan BCL2 Inhibitor
Goff, D., Smith, K. M., Shih, A. Y., Court-Recart, A., Sadarangani, A., Geron, I., … Jamieson, C. (2011). BCL2 Splice Isoform Switching Promotes Leukemia Stem Cell Survival and Sensitivity to a Novel Pan BCL2 Inhibitor. BLOOD, 118(21), 1176–76.

Inhibition of chronic myelogenous leukemia stem cells with novel wnt antagonists.
Kavalerchik, E., Gotlib, J., Geron, I., Abrahamsson, A., Wrasidlo, W., Goff, D., … Jamieson, C. (2006). Inhibition of chronic myelogenous leukemia stem cells with novel wnt antagonists. BLOOD, 108(11), 74A–75A.

A Detailed Flow Cytometry Analysis of the Immune System in Non-Leukemic Cells of Acute Myeloid Leukemia Demonstrates the Prognostic Significance of Lymphocyte Subsets
Ohgami, R. S., Alcasid, M., Ren, L., Gotlib, J. R., & Arber, D. A. (2013). A Detailed Flow Cytometry Analysis of the Immune System in Non-Leukemic Cells of Acute Myeloid Leukemia Demonstrates the Prognostic Significance of Lymphocyte Subsets. Presented at the 102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), BALTIMORE,MD: NATURE PUBLISHING GROUP.

Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update
Tefferi, A., Gotlib, J., & Pardanani, A. (2010). Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update. MAYO CLINIC PROCEEDINGS, 85(2), 158–164.

Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
Maxson, J. E., Gotlib, J., Pollyea, D. A., Fleischman, A. G., Agarwal, A., Eide, C. A., … Tyner, J. W. (2013). Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML. NEW ENGLAND JOURNAL OF MEDICINE, 368(19), 1781–90.

PTPN11 mutations are rare in adult patients with chronic myelomonocytic leukemia (CMML).
Loh, M. L., Vattikuti, S., Reynolds, M. G., Cheng, J. W., Lee, C. M., Gotlib, J., & Beran, M. (2003). PTPN11 mutations are rare in adult patients with chronic myelomonocytic leukemia (CMML). BLOOD, 102(11), 328B–328B.

Inhibition of JAK2 V617F-Induced erythroid skewing of hematopoietic stem cell differentiation with a selective JAK2 antagonist.
Geron, I., Barroga, C., Gotlib, J., Kavalerchik, E., Abrahamsson, A., Goff, D., … Jamieson, C. (2006). Inhibition of JAK2 V617F-Induced erythroid skewing of hematopoietic stem cell differentiation with a selective JAK2 antagonist. BLOOD, 108(11), 1033A–1033A.

Aberrant regulation of Wnt/beta-catenin pathway mediators in chronic myelogenous leukemia stem cells
Abrahamsson, A., Geron, I., Gotlib, J., Durocher, J., Creusot, R., Kavalerchik, E., … Jamieson, C. (2006). Aberrant regulation of Wnt/beta-catenin pathway mediators in chronic myelogenous leukemia stem cells. BLOOD, 108(11), 605A–605A.

Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib
Leu, H. S., Goff, D. J., Low-Marchelli, J., Recart, A. C. C., Smith, K. M., Ma, W., … Jamieson, C. (2012). Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib. BLOOD, 120(21).

Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia
Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Jones, C., Khan, S. A., Rajwanshi, R., … Zehnder, J. (2009). Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(15).

Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., … Alizadeh, A. A. (2009). Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). BLOOD, 114(22), 646–47.

The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): Interim results of a phase II trial
Gotlib, J., George, T. I., Corless, C., Linder, A., Ruddell, A., Akin, C., … Graubert, T. (2007). The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): Interim results of a phase II trial. BLOOD, 110(11), 1035A–1035A.

Chronic Myelogenous Leukemia
O'Brien, S., Abboud, C. N., Akhtari, M., Altman, J., Berman, E., DeAngelo, D. J., … Yunus, F. (2012). Chronic Myelogenous Leukemia. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(1), 64–110.

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Lancet, J. E., Gojo, I., Gotlib, J., Feldman, E. J., Greer, J., Liesveld, J. L., … Karp, J. E. (2007). A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. BLOOD, 109(4), 1387–94.

Chronic Myelogenous Leukemia
O'Brien, S., Berman, E., Borghaei, H., DeAngelo, D. J., Devetten, M. P., Devine, S., … Wetzler, M. (2009). Chronic Myelogenous Leukemia. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 7(9), 984–1023.

World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management
Gotlib, J. (2011). World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. AMERICAN JOURNAL OF HEMATOLOGY, 86(8), 678–88.

The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.
Gotlib, J., Maxson, J. E., George, T. I., & Tyner, J. W. (2013). The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood, 122(10), 1707–11.

Editorial.
Gotlib, J. (2013). Editorial. Therapeutic Advances in Hematology, 4(4), 235–236.

Hidden Mastocytosis in Acute Myeloid Leukemia With t(8;21)(q22;q22).
Johnson, R. C., Savage, N. M., Chiang, T., Gotlib, J. R., Cherry, A. M., Arber, D. A., & George, T. I. (2013). Hidden Mastocytosis in Acute Myeloid Leukemia With t(8;21)(q22;q22). American Journal of Clinical Pathology, 140(4), 525–35.

Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes.
Merker, J. D., Roskin, K. M., Ng, D., Pan, C., Fisk, D. G., King, J. J., … Gotlib, J. (2013). Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes. Haematologica, 98(11), 1689–96.

A 2-gene classifier for predicting response to the famesyltransferase inhibitor tipifarnib in acute myeloid leukemia
Raponi, M., Lancet, J. E., Fan, H., Dossey, L., Lee, G., Gojo, I., … Karp, J. E. (2008). A 2-gene classifier for predicting response to the famesyltransferase inhibitor tipifarnib in acute myeloid leukemia. BLOOD, 111(5), 2589–96.

Chronic Myelogenous Leukemia, Version 1.2014 Featured Updates to the NCCN Guidelines
O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., … Sundar, H. (2013). Chronic Myelogenous Leukemia, Version 1.2014 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(11), 1327–40.

A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition
Goff, D. J., Recart, A. C., Sadarangani, A., Chun, H.-J., Barrett, C. L., Krajewska, M., … Jamieson, C. H. M. (2013). A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition. CELL STEM CELL, 12(3), 316–28.

Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field
Valent, P., Gleich, G. J., Reiter, A., Roufosse, F., Weller, P. F., Hellmann, A., … Klion, A. D. (2012). Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. EXPERT REVIEW OF HEMATOLOGY, 5(2), 157–76.

Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes
Valent, P., Klion, A. D., Horny, H.-P., Roufosse, F., Gotlib, J., Weller, P. F., … Gleich, G. J. (2012). Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 130(3), 607-?

Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings.
Weinberg, O. K., Ohgami, R. S., Ma, L., Seo, K., Ren, L., Gotlib, J. R., … Arber, D. A. (2014). Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings. American Journal of Clinical Pathology, 142(2), 190–95.

Intensive serial biomarker profiling for the prediction of neutropenic Fever in patients with hematologic malignancies undergoing chemotherapy: a pilot study.
Chan, S. M., Chadwick, J., Young, D. L., Holmes, E., & Gotlib, J. (2014). Intensive serial biomarker profiling for the prediction of neutropenic Fever in patients with hematologic malignancies undergoing chemotherapy: a pilot study. Hematology Reports, 6(2), 5466-?

Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium
Tefferi, A., Abdel-Wahab, O., Cervantes, F., Crispino, J. D., Finazzi, G., Girodon, F., … Mughal, T. (2011). Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. BLOOD CANCER JOURNAL, 1.

The serum tryptase test: an emerging robust biomarker in clinical hematology
Valent, P., Sperr, W. R., Sotlar, K., Reiter, A., Akin, C., Gotlib, J., … Arock, M. (2014). The serum tryptase test: an emerging robust biomarker in clinical hematology. EXPERT REVIEW OF HEMATOLOGY, 7(5), 683–90.

Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal
Valent, P., Sotlar, K., Sperr, W. R., Escribano, L., Yavuz, S., Reiter, A., … Horny, H.-P. (2014). Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. ANNALS OF ONCOLOGY, 25(9), 1691–1700.

Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis
Valent, P., Escribano, L., Broesby-Olsen, S., Hartmann, K., Grattan, C., Brockow, K., … Arock, M. (2014). Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. ALLERGY, 69(10), 1267–74.

Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations
Ohgami, R. S., Ma, L., Merker, J. D., Gotlib, J. R., Schrijver, I., Zehnder, J. L., & Arber, D. A. (2015). Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. MODERN PATHOLOGY, 28(5), 706–14.

Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia
Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA RESEARCH, 38(12), 1441–45.

Chronic Myelogenous Leukemia, Version 1.2015 Clinical Practice Guidelines in Oncology
O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., … Sundar, H. (2014). Chronic Myelogenous Leukemia, Version 1.2015 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(11), 1590–1609.

Mast Cells in Systemic Mastocytosis Have Distinctly Brighter CD45 Expression by Flow Cytometry
Chisholm, K. M., Merker, J. D., Gotlib, J. R., Gitana, G., Lefterova, M., Zehnder, J. L., … Ohgami, R. S. (2015). Mast Cells in Systemic Mastocytosis Have Distinctly Brighter CD45 Expression by Flow Cytometry. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 143(4), 527–34.

Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms
Stein, B. L., Gotlib, J., Arcasoy, M., Nguyen, M. H., Shah, N., Moliterno, A., … Mesa, R. A. (2015). Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(4), 424–34.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., … Kantarjian, H. (2015). Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica, 100(4), 479–88.

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
Verstovsek, S., Gotlib, J., Gupta, V., Atallah, E., Mascarenhas, J., Quintas-Cardama, A., … Mesa, R. A. (2014). Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. ONCOTARGETS AND THERAPY, 7, 13–21.

CME Information: World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management
Gotlib, J. (2014). CME Information: World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. AMERICAN JOURNAL OF HEMATOLOGY, 89(3), 325–37.

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., … Kantarjian, H. M. (2012). A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. NEW ENGLAND JOURNAL OF MEDICINE, 366(9), 799–807.

Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening
Tyner, J. W., Yang, W. F., Bankhead, A., Fan, G., Fletcher, L. B., Bryant, J., … Loriaux, M. M. (2013). Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. CANCER RESEARCH, 73(1), 285–96.

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
Mesa, R. A., Kiladjian, J.-J., Verstovsek, S., Al-Ali, H. K., Gotlib, J., Gisslinger, H., … Harrison, C. (2014). Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. HAEMATOLOGICA, 99(2), 292–298.

Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study
Deeg, H. J., Gotlib, J., Beckham, C., Dugan, K., Holmberg, L., Schubert, M., … Greenberg, P. (2002). Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study. LEUKEMIA, 16(2), 162–64.

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib
Gleixner, K. V., Mayerhofer, M., Cerny-Reiterer, S., Hoermann, G., Rix, U., Bennett, K. L., … Valent, P. (2011). KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. BLOOD, 118(7), 1885–1898.

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside
Gotlib, J. (2013). JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 529–537.

Hereditary erythrocytosis, thrombocytosis and neutrophilia
Hong, W.-J., & Gotlib, J. (2014). Hereditary erythrocytosis, thrombocytosis and neutrophilia. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 27(2), 95–106.

Practical management of patients with myelofibrosis receiving ruxolitinib
Harrison, C., Mesa, R., Ross, D., Mead, A., Keohane, C., Gotlib, J., & Verstovsek, S. (2013). Practical management of patients with myelofibrosis receiving ruxolitinib. EXPERT REVIEW OF HEMATOLOGY, 6(5), 511–523.

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
Pardanani, A., Lasho, T., Finke, C., Oh, S. T., Gotlib, J., & Tefferi, A. (2010). LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. LEUKEMIA, 24(10), 1713–1718.

Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance
Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., … Lane, A. A. (2015). Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance. NATURE MEDICINE, 21(1), 71–75.

Myeloid and lymphoid Neoplasms with FGFR1 abnormalities: diagnostic and therapeutic challenges
Savage, N. M., Johnson, R. C., Gotlib, J., & George, T. I. (2013). Myeloid and lymphoid Neoplasms with FGFR1 abnormalities: diagnostic and therapeutic challenges. AMERICAN JOURNAL OF HEMATOLOGY, 88(5), 427–430.

Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review
Savage, N., George, T. I., & Gotlib, J. (2013). Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 35(5), 491–500.

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., … Kantarjian, H. M. (2013). The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. BRITISH JOURNAL OF HAEMATOLOGY, 161(4), 508–516.

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Tefferi, A., Cervantes, F., Mesa, R., Passamonti, F., Verstovsek, S., Vannucchi, A. M., … Barosi, G. (2013). Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD, 122(8), 1395–1398.

Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: A case review
Ustun, C., Savage, N. M., Gotlib, J., Bhalla, K., Manaloor, E., & George, T. I. (2012). Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: A case review. AMERICAN JOURNAL OF HEMATOLOGY, 87(2), 191–193.

Altered translation of GATA1 in Diamond-Blackfan anemia
Ludwig, L. S., Gazda, H. T., Eng, J. C., Eichhorn, S. W., Thiru, P., Ghazvinian, R., … Sankaran, V. G. (2014). Altered translation of GATA1 in Diamond-Blackfan anemia. NATURE MEDICINE, 20(7), 748–53.

Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium
Abdel-Wahab, O., Pardanani, A., Bernard, O. A., Finazzi, G., Crispino, J. D., Gisslinger, H., … Tefferi, A. (2012). Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium. AMERICAN JOURNAL OF HEMATOLOGY, 87(5), 562–568.

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., … Kantarjian, H. M. (2013). Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. HAEMATOLOGICA, 98(12), 1865–1871.

Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis
Gupta, V., Gotlib, J., Radich, J. P., Kroeger, N. M., Rondelli, D., Verstovsek, S., & Deeg, H. J. (2014). Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(9), 1274–81.

Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.
Liedtke, M., Dunn, T., Dinner, S., Coutré, S. E., Berube, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Leukemia Research, 38(12), 1441–45.

Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.
Khodadoust, M. S., Luo, B., Medeiros, B. C., Johnson, R. C., Ewalt, M. D., Schalkwyk, A. S., … Gotlib, J. (2016). Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia, 30(4), 947–50.

KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis
Arock, M., Sotlar, K., Akin, C., Broesby-Olsen, S., Hoermann, G., Escribano, L., … Valent, P. (2015). KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. LEUKEMIA, 29(6), 1223–1232.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., … Kantarjian, H. (2015). Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. HAEMATOLOGICA, 100(4), 482–91.

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I
Mesa, R. A., Verstoysek, S., Gupta, V., Mascarenhas, J. O., Atallah, E., Burn, T., … Gotlib, J. (2015). Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 15(4), 214–221.

Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leukemia & Lymphoma, 57(3), 609–15.

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis
Sasaki, K., Gotlib, J. R., Mesa, R. A., Newberry, K. J., Ravandi, F., Cortes, J. E., … Verstovsek, S. (2015). Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. LEUKEMIA & LYMPHOMA, 56(7), 2092–2097.

The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
Maxson, J. E., Luty, S. B., Macmaniman, J. D., Paik, J. C., Gotlib, J., Greenberg, P., … Tyner, J. W. (2016). The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. Clinical Cancer Research , 22(3), 757–64.

Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis
Gotlib, J. (2015). Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 10(4), 351–61.

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Vannucchi, A. M., Kantarjian, H. M., Kiladjian, J.-J., Gotlib, J., Cervantes, F., Mesa, R. A., … Verstovsek, S. (2015). A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. HAEMATOLOGICA, 100(9), 1139–45.

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
Jamieson, C., Hasserjian, R., Gotlib, J., Cortes, J., Stone, R., Talpaz, M., … Pozdnyakova, O. (2015). Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. JOURNAL OF TRANSLATIONAL MEDICINE, 13.

Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology
Hartmann, K., Escribano, L., Grattan, C., Brockow, K., Carter, M. C., Alvarez-Twose, I., … Valent, P. (2016). Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 137(1), 35–45.

A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., … Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 173(2), 253–59.

Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. LEUKEMIA & LYMPHOMA, 57(3), 609–15.

Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
Loh, M. L., Vattikuti, S., Schubbert, S., Reynolds, M. G., Carlson, E., Lieuw, K. H., … Shannon, K. M. (2004). Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. BLOOD, 103(6), 2325–31.

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.
Verstovsek, S., Gotlib, J., Gupta, V., Atallah, E., Mascarenhas, J., Quintas-Cardama, A., … Mesa, R. A. (2013). Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. OncoTargets and Therapy, 7, 13–21.

Insights into the molecular genetics of myeloproliferative neoplasms.
Nguyen, H. M., & Gotlib, J. (2012). Insights into the molecular genetics of myeloproliferative neoplasms. American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting, 411–18.

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
O'Brien, S., Berman, E., Borghaei, H., DeAngelo, D. J., Devetten, M. P., Devine, S., … Wetzler, M. (2009). NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network , 7(9), 984–1023.

Age-related mutations and chronic myelomonocytic leukemia
Mason, C. C., Khorashad, J. S., Tantravahi, S. K., Kelley, T. W., Zabriskie, M. S., Yan, D., … Deininger, M. W. (2016). Age-related mutations and chronic myelomonocytic leukemia. LEUKEMIA, 30(4), 906–13.

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., … Reiter, A. (2016). Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. NEW ENGLAND JOURNAL OF MEDICINE, 374(26), 2530–41.

Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.
Hinds, D. A., Barnholt, K. E., Mesa, R. A., Kiefer, A. K., Do, C. B., Eriksson, N., … Gotlib, J. (2016). Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood, 128(8), 1121–28.

Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia.
Alvarez-Twose, I., Martínez-Barranco, P., Gotlib, J., García-Montero, A., Morgado, J. M., Jara-Acevedo, M., … Orfao, A. (2016). Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia. Leukemia, 30(8), 1753–1756.

Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.
Ustun, C., Arock, M., Kluin-Nelemans, H. C., Reiter, A., Sperr, W. R., George, T., … Valent, P. (2016). Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica, 101(10), 1133–43.

The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia.
Alcasid, M., Ma, L., Gotlib, J. R., Arber, D. A., & Ohgami, R. S. (2017). The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia. International Journal of Laboratory Hematology.

NCCN Guidelines (R) Insights Chronic Myeloid Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines
Pallera, A., Altman, J. K., Berman, E., Abboud, C. N., Bhatnagar, B., Curtin, P., … Radich, J. P. (2016). NCCN Guidelines (R) Insights Chronic Myeloid Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(12), 1505–12.

Myeloproliferative Neoplasms, Version 2.2017
Mesa, R., Jamieson, C., Bhatia, R., Deininger, M. W., Gerds, A. T., Gojo, I., … Sundar, H. (2016). Myeloproliferative Neoplasms, Version 2.2017. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(12), 1572–1611.

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Verstovsek, S., Mesa, R. A., Gotlib, J., Gupta, V., DiPersio, J. F., Catalano, J. V., … Kantarjian, H. (2017). Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Journal of Hematology & Oncology, 10(1), 55-?

Chronic Myelogenous Leukemia, Version 1.2014.
O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., … Sundar, H. (2013). Chronic Myelogenous Leukemia, Version 1.2014. Journal of the National Comprehensive Cancer Network , 11(11), 1327–40.

Chronic myelogenous leukemia, version 1.2015.
O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., … Sundar, H. (2014). Chronic myelogenous leukemia, version 1.2015. Journal of the National Comprehensive Cancer Network , 12(11), 1590–1610.

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Mesa, R., Jamieson, C., Bhatia, R., Deininger, M. W., Gerds, A. T., Gojo, I., … Sundar, H. (2016). Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network , 14(12), 1572–1611.

Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.
Valent, P., Sotlar, K., Blatt, K., Hartmann, K., Reiter, A., Sadovnik, I., … Arock, M. (2017). Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. Leukemia.

Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.
Valent, P., Akin, C., Hartmann, K., Nilsson, G., Reiter, A., Hermine, O., … Metcalfe, D. D. (2017). Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Research.

A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.
Verstovsek, S., Savona, M. R., Mesa, R. A., Dong, H., Maltzman, J. D., Sharma, S., … Gotlib, J. (2017). A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis. British Journal of Haematology.

How I treat atypical chronic myeloid leukemia
Gotlib, J. (2017). How I treat atypical chronic myeloid leukemia. BLOOD, 129(7), 838–45.

Myeloid neoplasms with eosinophilia
Reiter, A., & Gotlib, J. (2017). Myeloid neoplasms with eosinophilia. BLOOD, 129(6), 704–14.

Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in Caenorhabditis elegans and Homo sapiens
Shoura, M., Gabdank, I., Merker, J., Gotlib, J., Levene, S., & Fire, A. (2017). Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in Caenorhabditis elegans and Homo sapiens. G3: GENES, GENOMES, GENETICS , 7, 3295–3303.

The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia
Lazzareschi, D., Cherry, A., Zehnder, J., Gotlib, J., Arber, D. A., Lacayo, N., & Ohgami, R. (2017). The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia. LABORATORY INVESTIGATION, 97, 358A–359A.

A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia
Chung, A., Hou, Y., Ohgami, R. S., Von Gehr, A., Fisk, D. G., Roskin, K. M., … Merker, J. D. (2017). A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. CANCER GENETICS, 216, 10–15.

The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia
Lazzareschi, D., Cherry, A., Zehnder, J., Gotlib, J., Arber, D. A., Lacayo, N., & Ohgami, R. (2017). The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia. MODERN PATHOLOGY, 30, 358A–359A.

Variability of PD-L1 expression in mastocytosis
Hatch, E. W., Geeze, M. B., Martin, C., Salama, M. E., Hartmann, K., Eisenwort, G., … George, T. I. (2018). Variability of PD-L1 expression in mastocytosis. BLOOD ADVANCES, 2(3), 189–99.

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal
Valent, P., Akin, C., Arock, M., Bock, C., George, T. I., Galli, S. J., … Horny, H.-P. (2017). Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBIOMEDICINE, 26, 17–24.

Cycling Toward Leukemia Stem Cell Elimination Wtih a Selective Sonic Hedgehog Antagonist
Shih, A. Y., Schairer, A., Barrett, C. L., Geron, I., Recart, A. C. C., Goff, D., … Jamieson, C. (2011). Cycling Toward Leukemia Stem Cell Elimination Wtih a Selective Sonic Hedgehog Antagonist. BLOOD, 118(21), 1613.

The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings
Segal, J., Dahl, G., Lacayo, N., Gotlib, J., & Ohgami, R. (2017). The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings. MODERN PATHOLOGY, 30, 376A.

Detailed Multiparameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study
Segal, J., Lacayo, N., Gotlib, J., & Ohgamt, R. (2017). Detailed Multiparameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study. MODERN PATHOLOGY, 30, 376A.

A Detailed Multi parameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study
Segal, J., Lacayo, N., Gotlib, J., & Ohgami, R. (2017). A Detailed Multi parameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study. LABORATORY INVESTIGATION, 97, 376A.

The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings
Segal, J., Dahl, G., Lacayo, N., Gotlib, J., & Ohgami, R. (2017). The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings. LABORATORY INVESTIGATION, 97, 376A.

Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia
Ustun, C., Williams, S., Skendzel, S., Kodal, B., Arock, M., Gotlib, J., … Miller, J. (2017). Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 92(5), E66–E68.

The Significance of Dim Cytoplasmic CD3 Expression in Acute Myeloid Leukemia: A Long-Term Retrospective Study Identifies an Association with Acute Promyelocytic Leukemia with FLT3-ITD Mutations
Kumar, J., Nagy, A., Lacayo, N., Gotlib, J., Zehnder, J. L., & Ohgami, R. (2018). The Significance of Dim Cytoplasmic CD3 Expression in Acute Myeloid Leukemia: A Long-Term Retrospective Study Identifies an Association with Acute Promyelocytic Leukemia with FLT3-ITD Mutations. MODERN PATHOLOGY, 31, 529.

Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD. AMER SOC HEMATOLOGY.

Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy
Pollyea, D. A., Zehnder, J. L., Coutre, S., Gotlib, J., Gallegos, L., Greenberg, P., … Medeiros, B. C. (2012). Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy. BLOOD. AMER SOC HEMATOLOGY.

GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition
Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., … Lane, A. A. (2014). GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition. BLOOD, 124(21).

A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Dinner, S., Dunn, T. J., Price, E., Coutré, S. E., Gotlib, J., Berube, C., … Liedtke, M. (2018). A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. International Journal of Hematology.

Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.
Verstovsek, S., Mesa, R. A., Foltz, L. M., Gupta, V., Mascarenhas, J., Ritchie, E. K., … Gotlib, J. R. (2014). Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis.
Mesa, R. A., Kiladjian, J.-J., Catalano, J. V., Devos, T., Egyed, M., Hellmann, A., … Gotlib, J. (2017). SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017734418.

Trispecific Killer Engager CD16xIL15xCD33 Enhances Alloreactivity of NK Cells Against Aberrant Mast Cells of Patients with Systemic Mastocytosis
Yun, H. D., Felices, M., Vallera, D. A., Cooley, S., Gotlib, J. R., Ustun, C., & Miller, J. S. (2018). Trispecific Killer Engager CD16xIL15xCD33 Enhances Alloreactivity of NK Cells Against Aberrant Mast Cells of Patients with Systemic Mastocytosis. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(3), S148–S149.

Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms
Mughal, T. I., Gotlib, J., Mesa, R., Koschmieder, S., Khoury, H. J., Cortes, J. E., … Abdel-Wahab, O. (2018). Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. LEUKEMIA RESEARCH, 67, 67–74.

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics
Ma, V. T., Boonstra, P. S., Menghrajani, K., Perkins, C., Gowin, K. L., Mesa, R. A., … Talpaz, M. (2018). Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 18(5), E201–E210.

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial
Mascarenhas, J., Hoffman, R., Talpaz, M., Gerds, A. T., Stein, B., Gupta, V., … Verstovsek, S. (2018). Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial. JAMA ONCOLOGY, 4(5), 652–59.

Myelophthisic marrow involved by breast cancer and acute myeloid leukemia
Shomali, W., & Gotlib, J. (2018). Myelophthisic marrow involved by breast cancer and acute myeloid leukemia. BLOOD, 131(9), 1036.

SOHO State-of-the-Art Update and Next Questions: MPN
Bose, P., Gotlib, J., Harrison, C. N., & Verstovsek, S. (2018). SOHO State-of-the-Art Update and Next Questions: MPN. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 18(1), 1–12.

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., … Passamonti, F. (2018). Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. LEUKEMIA RESEARCH, 69, 100–102.

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells
Yun, H. D., Felices, M., Vallera, D. A., Hinderlie, P., Cooley, S., Arock, M., … Miller, J. S. (2018). Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. BLOOD ADVANCES, 2(13), 1580–84.

Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Baird, J. H., & Gotlib, J. (2018). Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis. Current Hematologic Malignancy Reports.

Tailored Temozolomide Therapy for Elderly Patients with Acute Myeloid Leukemia.
Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Mignea, A., & Zehnder, J. (2008). Tailored Temozolomide Therapy for Elderly Patients with Acute Myeloid Leukemia. BLOOD, 112(11), 351.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., … Passamonti, F. (2018). Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. HAEMATOLOGICA, 103(9), E392–E394.

Chronic Myeloid Leukemia, Version 1.2019 Clinical Practice Guidelines in Oncology
Radich, J. P., Deininger, M., Abboud, C. N., Altman, J. K., Berman, E., Bhatia, R., … Sundar, H. (2018). Chronic Myeloid Leukemia, Version 1.2019 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(9), 1108–35.

Mast cell activation syndrome: Importance of consensus criteria and call for research
Valent, P., Akin, C., Bonadonna, P., Hartmann, K., Broesby-Olsen, S., Brockow, K., … Metcalfe, D. D. (2018). Mast cell activation syndrome: Importance of consensus criteria and call for research. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 142(3), 1008-+.

Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
Dao, K.-H. T., Tyner, J. W., & Gotlib, J. (2017). Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 12(5), 432–41.

World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management
Gotlib, J. (2017). World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. AMERICAN JOURNAL OF HEMATOLOGY, 92(11), 1243–59.

NCCN Guidelines (R) Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines
Mesa, R. A., Jamieson, C., Bhatia, R., Deininger, M. W., Fletcher, C. D., Gerds, A. T., … Sundar, H. (2017). NCCN Guidelines (R) Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(10), 1193–1207.

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
Verstovsek, S., Gotlib, J., Mesa, R. A., Vannucchi, A. M., Kiladjian, J.-J., Cervantes, F., … Gupta, V. (2017). Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. JOURNAL OF HEMATOLOGY & ONCOLOGY, 10, 156.

Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis
Gotlib, J. (2017). Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 31(4), 643-+.

A molecular roadmap for midostaurin in mastocytosis
Gotlib, J. (2017). A molecular roadmap for midostaurin in mastocytosis. BLOOD, 130(2), 98–100.

Quantitative Analysis of Ki67 in Mastocytosis Distinguishes Mast Cell Leukemia from Other Subtypes
Sojitra, P., Hatch, E. W., Martin, C., Gotlib, J. R., Ward, H., Lidke, D. S., & Geoige, T. (2017). Quantitative Analysis of Ki67 in Mastocytosis Distinguishes Mast Cell Leukemia from Other Subtypes. MODERN PATHOLOGY, 30, 378A.

Mast Cell Leukemia (MCL); Clinicopathologic Features of a Rare Disease
Davion, S., Wang, S., Silva, O., Sadigh, S., Arber, D. A., Bagg, A., … George, T. (2017). Mast Cell Leukemia (MCL); Clinicopathologic Features of a Rare Disease. MODERN PATHOLOGY, 30, 345A.

Quantitative Analysis of Ki67 in Mastocytosis Distinguishes Mast Cell Leukemia from Other Subtypes
Sojitra, P., Hatch, E. W., Martin, C., Gotlib, J. R., Ward, H., Lidke, D. S., & George, T. (2017). Quantitative Analysis of Ki67 in Mastocytosis Distinguishes Mast Cell Leukemia from Other Subtypes. LABORATORY INVESTIGATION, 97, 378A.

Mast Cell Leukemia (MCL); Clinicopathologic Features of a Rare Disease
Davion, S., Wang, S., Silva, O., Sadigh, S., Arber, D. A., Bagg, A., … George, T. (2017). Mast Cell Leukemia (MCL); Clinicopathologic Features of a Rare Disease. LABORATORY INVESTIGATION, 97, 345A.

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)
Sperr, W. R., Kundi, M., Elberink, H. O., van Anrooij, B., Gleixner, K. V., Hadzijusufovic, E., … Valent, P. (2016). Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry). BLOOD, 128(22).

Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis
Ustun, C., Gotlib, J., Popat, U., Artz, A., Litzow, M., Reiter, A., … Valent, P. (2016). Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(8), 1348–56.

To Treat or Not to Treat: A Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors
Menghrajani, K., Boonstra, P. S., Weber, A., Perkins, C., Gowin, K., Huong Nguyen, … Talpaz, M. (2015). To Treat or Not to Treat: A Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 15, S236.

PD-1/PD-L1 Are Novel Therapeutic Targets for Mastocytosis
Geeze, M., Hatch, E., Martin, C., Perkins, S. L., Hartmann, K., Valent, P., … George, T. I. (2016). PD-1/PD-L1 Are Novel Therapeutic Targets for Mastocytosis. MODERN PATHOLOGY, 29, 346A.

PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks
Verstovsek, S., Mesa, R. A., Foltz, L. M., Gupta, V., Mascarenhas, J. O., Ritchie, E. K., … Gotlib, J. (2015). PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. BLOOD, 126(23).

A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis
Verstovsek, S., Savona, M. R., Mesa, R. A., Oh, S., Dong, H., Thai, D., & Gotlib, J. (2015). A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis. BLOOD. AMER SOC HEMATOLOGY.

PD-1/PD-L1 Are Novel Therapeutic Targets for Mastocytosis
Geeze, M., Hatch, E., Martin, C., Perkins, S. L., Hartmann, K., Valent, P., … George, T. I. (2016). PD-1/PD-L1 Are Novel Therapeutic Targets for Mastocytosis. LABORATORY INVESTIGATION, 96, 346A.

World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management
Gotlib, J. (2015). World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. AMERICAN JOURNAL OF HEMATOLOGY, 90(11), 1078–89.

A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis.
Sasaki, K., Gotlib, J. R., Mesa, R. A., Ravandi, F., Cortes, J. E., Kelly, P. F., … Verstovsek, S. (2014). A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Eosinophilic myeloproliferative disorders
Gotlib, J. (2014). Eosinophilic myeloproliferative disorders. CANCER CONSULT: EXPERTISE FOR CLINICAL PRACTICE, 167–75.

A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers
Kamal, M., Boonstra, P. S., Weber, A. A., Perkins, C., Gowin, K. L., Huong (Marie) Nguyen, … Talpaz, M. (2014). A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers. BLOOD, 124(21).

A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM)
Passamonti, F., Alessandro, V., Domenica, C., Alessandro, R., Enrica, M., Jacques, K. J., … Cazzola, M. (2014). A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM). BLOOD, 124(21).

Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial
Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., … Reiter, A. (2014). Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. BLOOD, 124(21).

Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival
Mason, C. C., Khorashad, J. S., Tantravahi, S. K., Kelley, T. W., Pomicter, A. D., Iovino, A. J., … Deininger, M. W. (2014). Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival. BLOOD, 124(21).

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results
Verstovsek, S., Mesa, R. A., Foltz, L. M., Gupta, V., Mascarenhas, J. O., Ritchie, E. K., … Gotlib, J. R. (2014). Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. BLOOD, 124(21).

Two faces of ET: CALR and JAK2
Chao, M. P., & Gotlib, J. (2014). Two faces of ET: CALR and JAK2. BLOOD, 123(10), 1438–40.

Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.
Verstovsek, S., Mesa, R. A., Gotlib, J. R., Gupta, V., DiPersio, J. F., Catalano, J. V., … Kantarjian, H. (2012). Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. JOURNAL OF CLINICAL ONCOLOGY, 30(15).

Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I
Mesa, R. A., Verstovsek, S., Gupta, V., Mascarenhas, J., Atallah, E., Sun, W., … Gotlib, J. (2012). Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I. BLOOD, 120(21).

Clinical Benefits of Ruxolitinib Therapy in Myelofibrosis Patients with Varying Degrees of Splenomegaly and Symptoms
Mesa, R. A., Gotlib, J., Kantarjian, H. M., Sun, W., & Verstovsek, S. (2012). Clinical Benefits of Ruxolitinib Therapy in Myelofibrosis Patients with Varying Degrees of Splenomegaly and Symptoms. BLOOD, 120(21).

Effect of Ruxolitinib On the Incidence of Splenectomy in Patients with Myelofibrosis: A Retrospective Analysis of Data From Ruxolitinib Clinical Trials
Verstovsek, S., Kiladjian, J.-J., Mesa, R. A., Vannucchi, A. M., Gotlib, J., Barosi, G., … Harrison, C. N. (2012). Effect of Ruxolitinib On the Incidence of Splenectomy in Patients with Myelofibrosis: A Retrospective Analysis of Data From Ruxolitinib Clinical Trials. BLOOD. AMER SOC HEMATOLOGY.

Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
Pardanani, A., Gotlib, J., Gupta, V., Roberts, A. W., Wadleigh, M., Sirhan, S., … Tefferi, A. (2012). Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. BLOOD, 120(21).

A Germline Variant in the TERT Gene Is a Novel Predisposition Allele Associated with Myeloproliferative Neoplasms
Hinds, D. A., Barnholt, K. E., Zehnder, J. L., Kiefer, A. K., Do, C. B., Eriksson, N., … Gotlib, J. (2012). A Germline Variant in the TERT Gene Is a Novel Predisposition Allele Associated with Myeloproliferative Neoplasms. BLOOD. AMER SOC HEMATOLOGY.

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., … Kantarjian, H. M. (2012). Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I. BLOOD, 120(21).

KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial
Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., … Reiter, A. (2012). KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. BLOOD, 120(21).

An Expanded Multicenter Phase I/II Study of CYT387, a JAK-1/2 Inhibitor for the Treatment of Myelofibrosis
Pardanani, A., Gotlib, J., Gupta, V., Roberts, A. W., Wadleigh, M., Sirhan, S., … Tefferi, A. (2011). An Expanded Multicenter Phase I/II Study of CYT387, a JAK-1/2 Inhibitor for the Treatment of Myelofibrosis. BLOOD, 118(21), 1645.

Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF
Mesa, R. A., Gotlib, J., Gupta, V., DiPersio, J. F., Catalano, J., Deininger, M. W., … Verstovsek, S. (2011). Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF. BLOOD, 118(21), 1642–43.

A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes
Pollyea, D. A., Raval, A., Kusler, B., Gotlib, J. R., Alizadeh, A. A., & Mitchell, B. S. (2010). A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes. BLOOD, 116(21), 788.

Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly,, Disease-Related Symptoms, and JAK2V617F Allele Burden
Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., … Tefferi, A. (2010). Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly,, Disease-Related Symptoms, and JAK2V617F Allele Burden. BLOOD, 116(21), 205–6.

KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial
Gotlib, J., DeAngelo, D. J., George, T. I., Corless, C. L., Linder, A., Langford, C., … Graubert, T. (2010). KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial. BLOOD, 116(21), 144.

Eosinophilic Disorders: Differential Diagnosis and Management
Gotlib, J. (2011). Eosinophilic Disorders: Differential Diagnosis and Management. MYELOPROLIFERATIVE NEOPLASMS- BIOLOGY AND THERAPY, 181–203.

RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies
Tyner, J. W., Loriaux, M., Willis, S. G., Chang, B. H., Bicocca, V. T., Oh, S. T., … Druker, B. J. (2009). RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies. BLOOD. AMER SOC HEMATOLOGY.

AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome.
Seetharam, M., Weinberg, O. K., Ren, L., Ma, L., Seo, K., Zehnder, J. L., … Arber, D. A. (2009). AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome. BLOOD, 114(22), 1035.

A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden
Pardanani, A. D., Gotlib, J. R., Jamieson, C., Cortes, J., Talpaz, M., Stone, R., … Tefferi, A. (2009). A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden. BLOOD, 114(22), 314–15.

Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis
Tyner, J. W., Fletcher, L., Yang, W., Oh, S. T., Gotlib, J. R., Deininger, M. W. N., … Loriaux, M. (2009). Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis. BLOOD. AMER SOC HEMATOLOGY.

Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis.
Tyner, J. W., Erickson, H., Oh, S., Gotlib, J. R., Deininger, M. W. N., Druker, B. J., & Loriaux, M. (2008). Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis. BLOOD. AMER SOC HEMATOLOGY.

RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients
Tyner, J. W., Loriaux, M., Willis, S. G., Chang, B., Bicocca, V. T., Oh, S., … Druker, B. J. (2008). RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients. BLOOD. AMER SOC HEMATOLOGY.

A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis
Pardanani, A. D., Gotlib, J., Jamieson, C., Cortes, J., Talpaz, M., Stone, R. M., … Tefferi, A. (2008). A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis. BLOOD, 112(11), 43–44.

Core-binding factor acute myeloid leukemia with t(8;21) Risk factors and a novel scoring system (I-CBFit)
Ustun, C., Morgan, E., Moodie, E. E. M., Pullarkat, S., Yeung, C., Broesby-Olsen, S., … Borthakur, G. (2018). Core-binding factor acute myeloid leukemia with t(8;21) Risk factors and a novel scoring system (I-CBFit). CANCER MEDICINE, 7(9), 4447–55.

THE NUMBER AND TYPE OF MUTATIONS IN CANCER-LINKED GENES IS ASSOCIATED WITH OUTCOME OF SYSTEMIC MASTOCYTOSIS.
Munoz-Gonzalez, J. I., Jara-Acevedo, M., Alvarez-Twose, I., Merker, J. D., Teodosio, C., Henriques, A., … Garcia-Montero, A. C. (2018). THE NUMBER AND TYPE OF MUTATIONS IN CANCER-LINKED GENES IS ASSOCIATED WITH OUTCOME OF SYSTEMIC MASTOCYTOSIS. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 40, 102.

PLATELET TRANSCRIPTOMIC SIGNATURES IN MYELOPROLIFERATIVE NEOPLASMS
Krishnan, A., Perkins, C., Gotlib, J., & Zehnder, J. (2018). PLATELET TRANSCRIPTOMIC SIGNATURES IN MYELOPROLIFERATIVE NEOPLASMS. AMERICAN JOURNAL OF HEMATOLOGY, 93(9), E34.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.
Barraco, D., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., … Passamonti, F. (2018). Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer Journal, 8(10), 89.

Impact of somatic and germline mutations on the outcome of systemic mastocytosis.
Munoz-Gonzalez, J. I., Jara-Acevedo, M., Alvarez-Twose, I., Merker, J. D., Teodosio, C., Hou, Y., … Garcia-Montero, A. C. (2018). Impact of somatic and germline mutations on the outcome of systemic mastocytosis. Blood Advances, 2(21), 2814–28.

The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.
Valent, P., Oude Elberink, J. N., Gorska, A., Lange, M., Zanotti, R., van Anrooij, B., … Sperr, W. R. (2018). The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. The Journal of Allergy and Clinical Immunology. In Practice.

The new tool "KIT" in advanced systemic mastocytosis.
Shomali, W., & Gotlib, J. (2018). The new tool "KIT" in advanced systemic mastocytosis. Hematology. American Society of Hematology. Education Program, 2018(1), 127–36.

Systemic Mastocytosis, Version 2.2019
Gotlib, J., Gerds, A. T., Bose, P., Castells, M. C., Deininger, M. W., Gojo, I., … Sundar, H. (2018). Systemic Mastocytosis, Version 2.2019. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(12), 1500–1537.

Proposed Diagnostic Algorithm for Patients With Suspected Mast Cell Activation Syndrome.
Valent, P., Akin, C., Bonadonna, P., Hartmann, K., Brockow, K., Niedoszytko, M., … Metcalfe, D. D. (2019). Proposed Diagnostic Algorithm for Patients With Suspected Mast Cell Activation Syndrome. The Journal of Allergy and Clinical Immunology. In Practice.

Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.
Li, P., Shahmarvand, N., Lynch, D., Gotlib, J. R., Merker, J. D., Zehnder, J. L., … Ohgami, R. S. (2019). Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist. International Journal of Laboratory Hematology.

Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells
Chae, H.-D., Murphy, L. C., Donato, M., Lee, A. G., Sweet-Cordero, E. A., Abidi, P., … Sakamoto, K. M. (2018). Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells. BLOOD. AMER SOC HEMATOLOGY.

Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients
Mora, B., Rumi, E., Guglielmelli, P., Barraco, D., Maffioli, M., Rambaldi, A., … Passamonti, F. (2018). Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients. BLOOD, 132.

Comprehensive Cytokine Profiling of Patients with Advanced Systemic Mastocytosis Treated with Midostaurin
Ediriwickrema, A., DeAngelo, D. J., George, T. I., Rosenberg-Hasson, Y., Perkins, C., Langford, C., & Gotlib, J. R. (2018). Comprehensive Cytokine Profiling of Patients with Advanced Systemic Mastocytosis Treated with Midostaurin. BLOOD, 132.

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Dao, K.-H., Collins, R. H., Cortes, J. E., Deininger, M. W., Druker, B. J., Gotlib, J. R., … Winton, E. F. (2018). Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia. BLOOD. AMER SOC HEMATOLOGY.

Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM)
Gotlib, J. R., Radia, D., DeAngelo, D. J., Bose, P., Drummond, M. W., Hexner, E. O., … Deininger, M. W. (2018). Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM). BLOOD, 132.

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1)
Verstovsek, S., Vannucchi, A. M., Rambaldi, A., Gotlib, J. R., Mead, A. J., Hochhaus, A., … Reiter, A. (2018). Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1). BLOOD, 132.

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
Masarova, L., Verstovsek, S., Hidalgo-Lopez, J. E., Pemmaraju, N., Bose, P., Estrov, Z., … Daver, N. (2018). A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. BLOOD, 132(16), 1664–74.

Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis
Menghrajani, K., Boonstra, P. S., Mercer, J. A., Perkins, C., Gowin, K. L., Weber, A. A., … Talpaz, M. (2019). Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. LEUKEMIA & LYMPHOMA, 60(4), 1036–42.

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.
Valent, P., Akin, C., Arock, M., Bock, C., George, T. I., Galli, S. J., … Horny, H.-P. P. (2017). Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBioMedicine, 26, 17–24.

Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.
Hartmann, K., Escribano, L., Grattan, C., Brockow, K., Carter, M. C., Alvarez-Twose, I., … Valent, P. (2016). Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. The Journal of Allergy and Clinical Immunology, 137(1), 35–45.

Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in Caenorhabditis elegans and Homo sapiens.
Shoura, M. J., Gabdank, I., Hansen, L., Merker, J., Gotlib, J., Levene, S. D., & Fire, A. Z. (2017). Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in Caenorhabditis elegans and Homo sapiens. G3 (Bethesda, Md.), 7(10), 3295–3303.

Emerging translational science discoveries, clonal approaches and treatment trends in chronic myeloproliferative neoplasms.
Mughal, T. I., Pemmaraju, N., Radich, J. P., Deininger, M. W., Kucine, N., Kiladjian, J.-J., … Van Etten, R. A. (2019). Emerging translational science discoveries, clonal approaches and treatment trends in chronic myeloproliferative neoplasms. Hematological Oncology.

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
Mora, B., Rumi, E., Guglielmelli, P., Barraco, D., Maffioli, M., Rambaldi, A., … Passamonti, F. (2019). Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine.

Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist
Li, P., Shahmarvand, N., Lynch, D., Gotlib, J. R., Merker, J. D., Zehnder, J. L., … Ohgami, R. S. (2019). Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 41(3), 345–52.

MYC regulates the HIF-2alpha stemness pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells.
Das, B., Pal, B., Bhuyan, R., Li, H., Sarma, A., Gayan, S., … Felsher, D. W. (2019). MYC regulates the HIF-2alpha stemness pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells. Cancer Research.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
Barraco, D., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., … Passamonti, F. (2018). Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. BLOOD CANCER JOURNAL, 8.

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.
Gotlib, J., Baird, J. H., George, T. I., Langford, C., Reyes, I., Abuel, J., … Verstovsek, S. (2019). A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Advances, 3(15), 2264–71.

Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis.
Zhang, H., Wilmot, B., Bottomly, D., Dao, K.-H. T., Stevens, E., Eide, C. A., … Tyner, J. W. (2019). Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. Blood.

TIM3 and Galectin-9 are Novel Therapeutic Targets for Mastocytosis
Williams, M., George, T., Tripp, S., Deininger, M., Gotlib, J., & Hartmann, K. (2019). TIM3 and Galectin-9 are Novel Therapeutic Targets for Mastocytosis. LABORATORY INVESTIGATION, 99.

TIM3 and Galectin-9 are Novel Therapeutic Targets for Mastocytosis
Williams, M., George, T., Tripp, S., Deininger, M., Gotlib, J., & Hartmann, K. (2019). TIM3 and Galectin-9 are Novel Therapeutic Targets for Mastocytosis. MODERN PATHOLOGY, 32.

World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali, W., & Gotlib, J. (2019). World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. American Journal of Hematology.

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.
Jawhar, M., Schwaab, J., Álvarez-Twose, I., Shoumariyeh, K., Naumann, N., Lübke, J., … Reiter, A. (2019). MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1900640.

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study of the MYSEC group.
Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Barraco, D., Rambaldi, A., … Passamonti, F. (2019). Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study of the MYSEC group. American Journal of Hematology.

A Kindred with a ß-Globin Base Substitution [ß89(F5)Ser?Arg (AGT>AGG); HBB: c.270T>G] Resulting in Hemoglobin Vanderbilt.
Shomali, W., Brar, R., Arekapudi, S. R., & Gotlib, J. R. (2019). A Kindred with a ß-Globin Base Substitution [ß89(F5)Ser?Arg (AGT>AGG); HBB: c.270T>G] Resulting in Hemoglobin Vanderbilt. Hemoglobin, 1–4.

International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study.
Sperr, W. R., Kundi, M., Alvarez-Twose, I., van Anrooij, B., Oude Elberink, J. N., Gorska, A., … Valent, P. (2019). International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. The Lancet. Haematology.

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study
Verstovsek, S., Hasserjian, R. P., Pozdnyakova, O., Veletic, I., Mesa, R. A., Foltz, L., … Gotlib, J. R. (2018). PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. BLOOD, 132.

Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry.
Kluin-Nelemans, H. C., Reiter, A., Illerhaus, A., van Anrooij, B., Hartmann, K., Span, L. F., … Sperr, W. R. (2019). Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia.

New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.
Arock, M., Sotlar, K., Gotlib, J., Sperr, W. R., Hartmann, K., Schwartz, L. B., … Valent, P. (2019). New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. Leukemia & Lymphoma, 1–9.

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao, K.-H. T., Gotlib, J., Deininger, M. M., Oh, S. T., Cortes, J. E., Collins, R. H., … Tyner, J. W. (2019). Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1900895.

New Developments in Diagnosis, Prognostication, and Treatment of Advanced Systemic Mastocytosis.
Reiter, A., George, T. I., & Gotlib, J. R. (2020). New Developments in Diagnosis, Prognostication, and Treatment of Advanced Systemic Mastocytosis. Blood.

Clinical Features and Survival of Patients with Indolent Systemic Mastocytosis defined by the Updated WHO Classification.
Trizuljak, J., Sperr, W. R., Nekvindová, L., Oude Elberink, H., Gleixner, K. V., Gorska, A., … Valent, P. (2020). Clinical Features and Survival of Patients with Indolent Systemic Mastocytosis defined by the Updated WHO Classification. Allergy.

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A. T., O'Connell, C., … Mascarenhas, J. (2020). Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood.

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
Jawhar, M., Schwaab, J., Alvarez-Twose, I., Shoumariyeh, K., Naumann, N., Luebke, J., … Reiter, A. (2020). MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. ONCOLOGY RESEARCH AND TREATMENT. KARGER.

Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology.
Ozturk, K., Cayci, Z., Gotlib, J., Akin, C., George, T. I., & Ustun, C. (2020). Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology. Blood Reviews, 100693.

Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Hartmann, K., Gotlib, J., Akin, C., Hermine, O., Awan, F. T., Hexner, E., … Kluin-Nelemans, H. C. (2020). Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. The Journal of Allergy and Clinical Immunology.

Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
Azizi, A., Ediriwickrema, A., Dutta, R., Patel, S. A., Shomali, W., Medeiros, B., … Zhang, T. (2020). Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leukemia & Lymphoma, 1–8.

Risk and Management of Patients with Mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) Pandemic: Expert Opinions.
Valent, P., Akin, C., Bonadonna, P., Brockow, K., Niedoszytko, M., Nedoszytko, B., … Hartmann, K. (2020). Risk and Management of Patients with Mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) Pandemic: Expert Opinions. The Journal of Allergy and Clinical Immunology.

Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
Coltoff, A., Mesa, R., Gotlib, J., Shulman, J., Rampal, R. K., Siwoski, O., … Mascarenhas, J. (2020). Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera. Clinical Lymphoma, Myeloma & Leukemia.

Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts.
Valent, P., Akin, C., Hartmann, K., Nilsson, G., Reiter, A., Hermine, O., … Galli, S. J. (2020). Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. Theranostics, 10(23), 10743–68.

Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure.
Ustun, C., Morgan, E. A., Ritz, E. M., Vestergaard, H., Pullarkat, S., Kluin, P. M., … Marcucci, G. (2020). Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. International Journal of Laboratory Hematology.

Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
Gerds, A. T., Gotlib, J., Bose, P., Deininger, M. W., Dunbar, A., Elshoury, A., … Sundar, H. (2020). Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 18(9), 1248–69.

Dynamic and Time-To-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naive Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib
McLornan, D., Mesa, R., Catalano, J., Cervantes, F., Devos, T., Egyed, M., … Kowalski, M. (2020). Dynamic and Time-To-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naive Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., … Sundar, H. (2020). Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 18(10), 1385–1415.

Practical Management of Adverse Events in Patients With Advanced Systemic Mastocytosis Receiving Midostaurin.
Gotlib, J., Kluin-Nelemans, H. C., Akin, C., Hartmann, K., Valent, P., & Reiter, A. (2020). Practical Management of Adverse Events in Patients With Advanced Systemic Mastocytosis Receiving Midostaurin. Expert Opinion on Biological Therapy.

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
Kluin-Nelemans, H. C., Jawhar, M., Reiter, A., van Anrooij, B., Gotlib, J., Hartmann, K., … Sperr, W. R. (2021). Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. THERANOSTICS, 11(1), 292–303.

Sustained Complete Molecular Remission With Imatinib Monotherapy in a Child Presenting With Blast Phase FIP1L1-PDGFRA-Associated Myeloid Neoplasm With Eosinophilia.
Jain, J., Weinzierl, E. P., Saxe, D., Bergsagel, J., Gotlib, J., Reiter, A., & Raikar, S. S. (2020). Sustained Complete Molecular Remission With Imatinib Monotherapy in a Child Presenting With Blast Phase FIP1L1-PDGFRA-Associated Myeloid Neoplasm With Eosinophilia. HemaSphere, 4(6), e486.

Scoring the risk of having systemic mastocytosis in adult patients with mastocytosis in the skin.
Fuchs, D., Kilbertus, A., Kofler, K., von Bubnoff, N., Shoumariyeh, K., Zanotti, R., … Valent, P. (2020). Scoring the risk of having systemic mastocytosis in adult patients with mastocytosis in the skin. The Journal of Allergy and Clinical Immunology. In Practice.

Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors
Wernig, G. (2021). Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors. Proceedings of the National Academy of Sciences, 118 (2)(Jan 2021).

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
Kluin-Nelemans, H. C., Jawhar, M., Reiter, A., van Anrooij, B., Gotlib, J., Hartmann, K., … Sperr, W. R. (2021). Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. Theranostics, 11(1), 292–303.

Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors.
Cui, L., Moraga, I., Lerbs, T., Van Neste, C., Wilmes, S., Tsutsumi, N., … Wernig, G. (2021). Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors. Proceedings of the National Academy of Sciences of the United States of America, 118(2).

What your HalphaT says about you.
Gotlib, J. (2021). What your HalphaT says about you. Blood, 137(2), 151–53.

Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML.
Ladha, A., Hui, G., Cheung, E., Berube, C., Coutre, S. E., Gotlib, J., … Mannis, G. N. (2021). Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML. Leukemia & Lymphoma, 1–6.

Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.
Muñoz-González, J. I., Álvarez-Twose, I., Jara-Acevedo, M., Zanotti, R., Perkins, C., Jawhar, M., … Orfao, A. (2021). Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. The Lancet. Haematology.

Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis (ECNM).
Aberer, E., Sperr, W. R., Bretterklieber, A., Avian, A., Hadzijusufovic, E., Kluin-Nelemans, H. C., … Valent, P. (2021). Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis (ECNM). The Journal of Investigative Dermatology.

Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.
Gotlib, J., George, T., Carter, M. C., Austen, K. F., Bochner, B., Dwyer, D., … Akin, C. (2021). Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference. The Journal of Allergy and Clinical Immunology.

Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali, W., & Gotlib, J. (2021). Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors. International Journal of Molecular Sciences, 22(6).

COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).
Bonadonna, P., Brockow, K., Niedoszytko, M., Elberink, H. O., Akin, C., Nedoszytko, B., … Valent, P. (2021). COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). The Journal of Allergy and Clinical Immunology. In Practice.

Avapritinib induces responses in patients with advanced systemic mastocytosis, regardless of prior midostaurin therapy
Radia, D., Drummond, M. W., Gotlib, J., George, T. I., Quiery, A. T., Winton, E., … DeAngelo, D. J. (2021). Avapritinib induces responses in patients with advanced systemic mastocytosis, regardless of prior midostaurin therapy. BRITISH JOURNAL OF HAEMATOLOGY. WILEY.

A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)
Oh, S., Kiladjian, J.-J., Palandri, F., Gotlib, J., Mohan, S., Ali, H., … Verstovsek, S. (2021). A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104). BRITISH JOURNAL OF HAEMATOLOGY. WILEY.

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).
Han, S. Y., Mrozek, K., Voutsinas, J., Wu, Q., Morgan, E. A., Vestergaard, H., … Yeung, C. C. (2021). Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Advances, 5(10), 2481–2489.

Results from PIONEER: a randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis
Radia, D. H., Sabato, V., Castells, M., Akin, C., Elberink, H. O., Tashi, T., … Gotlib, J. (2021). Results from PIONEER: a randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis. BRITISH JOURNAL OF HAEMATOLOGY. WILEY.

Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF).
Taylor, F., Li, X., Yip, C., Padilla, B., Mar, B., Green, T., … Gotlib, J. (2021). Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF). Leukemia Research, 108, 106606.

Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.
Tremblay, D., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M., Kuykendall, A., … Mascarenhas, J. (2021). Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leukemia Research, 109, 106629.

Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
Naumann, N., Lubke, J., Shomali, W., Reiter, L., Horny, H.-P., Jawhar, M., … Schwaab, J. (2021). Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations. British Journal of Haematology.

Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review.
Gulen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., … Valent, P. (2021). Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. The Journal of Allergy and Clinical Immunology. In Practice.

Diagnosis and management of neutrophilic myeloid neoplasms.
Schwede, M., Gotlib, J., & Shomali, W. (2021). Diagnosis and management of neutrophilic myeloid neoplasms. Clinical Advances in Hematology & Oncology : H&O, 19(7), 450–459.

Diagnosis and Management of Neutrophilic Myeloid Neoplasms
Schwede, M., Gotlib, J., & Shomali, W. (2021). Diagnosis and Management of Neutrophilic Myeloid Neoplasms. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 19(7), 450–459.

PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM).
DeAngelo, D. J., Reiter, A., Radia, D., Deininger, M. W., George, T. I., Panse, J., … Gotlib, J. (2021). PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM). CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104).
Oh, S. T., Kiladjian, J.-J., Palandri, F., Gotlib, J. R., Mohan, S., Ali, H., … Verstovsek, S. (2021). A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104). CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Current and future status of JAK inhibitors
McLornan, D. P., Pope, J. E., Gotlib, J., & Harrison, C. N. (2021). Current and future status of JAK inhibitors. LANCET, 398(10302), 803–816.

A novel activating JAK1 mutation in chronic eosinophilic leukemia.
Shomali, W., Damnernsawad, A., Theparee, T., Sampson, D., Morrow, Q., Yang, F., … Gotlib, J. R. (2021). A novel activating JAK1 mutation in chronic eosinophilic leukemia. Blood Advances.

Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.
Chen, J. A., Hou, Y., Roskin, K. M., Arber, D. A., Bangs, C. D., Baughn, L. B., … Gotlib, J. (2021). Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. Blood Advances, 5(17), 3492–3496.

Efficacy and Safety of <= 200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies
Radia, D., DeAngelo, D., Deininger, M. W., Reiter, A., Sen, J., Lin, H. M., … Gotlib, J. (2021). Efficacy and Safety of <= 200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Treatment
Reiter, A., Cross, N. C. P., & Gotlib, J. (2021). Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Treatment. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

Chronic Eosinophilic Leukemia: Diagnosis and Therapy
Gotlib, J., Shomali, W., & Reiter, A. (2021). Chronic Eosinophilic Leukemia: Diagnosis and Therapy. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

World Health Organization-defined eosinophilic disorders: 2021 update on diagnosis, risk stratification, and management.
Shomali, W., & Gotlib, J. (2021). World Health Organization-defined eosinophilic disorders: 2021 update on diagnosis, risk stratification, and management. American Journal of Hematology.

Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis.
Zanotti, R., Bonifacio, M., Lucchini, G., Sperr, W. R., Scaffidi, L., van Anrooij, B., … Valent, P. (2021). Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. Leukemia.

Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms
Shen, Z., Du, W., Perkins, C., Fechter, L., Natu, V., Maecker, H., … Krishnan, A. (2021). Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. CELL REPORTS MEDICINE, 2(10).

Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms.
Shen, Z., Du, W., Perkins, C., Fechter, L., Natu, V., Maecker, H., … Krishnan, A. (2021). Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. Cell Reports. Medicine, 2(10), 100425.

Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., … Metcalfe, D. D. (2021). Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HEMASPHERE, 5(11).

Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
DeAngelo, D. J., Radia, D. H., George, T. I., Robinson, W. A., Quiery, A. T., Drummond, M. W., … Gotlib, J. (2021). Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nature Medicine.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
Gotlib, J., Reiter, A., Radia, D. H., Deininger, M. W., George, T. I., Panse, J., … DeAngelo, D. J. (2021). Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nature Medicine.

Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.
Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., … Metcalfe, D. D. (2021). Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere, 5(11), e646.

Comparison of the Transcriptomic Signatures in Pediatric and Adult CML.
Youn, M., Smith, S. M., Lee, A. G., Chae, H.-D., Spiteri, E., Erdmann, J., … Sakamoto, K. M. (1800). Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers, 13(24).

Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis.
Lubke, J., Schwaab, J., Naumann, N., Horny, H.-P., WeiSS, C., Metzgeroth, G., … Reiter, A. (2022). Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2101849.